AntiDFS70 Lupus Nephritis

Study Overview
=================
Brief Summary
-----------------
Systemic lupus erythematous (SLE) is a heterogeneous autoimmune disease that involve many different organs and display a variable clinical course. The prevalence of SLE varies across gender, race/ethnicity, and geographic regions. SLE demonstrates a striking female predominance with a peak incidence of disease during the Reproductive years. In adults, the female to male ratio is 10- 15:1(1)( 2) Clinical features in individual patients can be quite variable and range from mild joint and skin involvement to severe, life-threatening internal organ disease. Constitutional symptoms, rash, mucosal ulcers, inflammatory polyarthritis, photosensitivity, and serositis are the most common clinical features of the disease. (3) (4) Anti-DFS70 antibodie) and their clinical associations remain an immunological paradox. Unlike other antinuclear antibodies , there is a growing body of evidence that anti-DFS70 antibodies, when present in high titers and in isolation (without accompanying other antibodies), are useful to aid in the exclusion of antinuclear antibodies associated rheumatic diseases. (8) Anti-DFS70 antibodies were not associated with lupus nephritis development in Systemic lupus erythematosus patients but were associated with anti-dsDNA antibodies , proliferative lupus nephritis, and renal activity index . This suggests their potential to serve as a non-histological biomarker for lupus nephritis subclass and activity status. (8)

Official Title
-----------------
Anti-DFS70 Antibodies and it's Relationship With Systemic Lupus Erythematosus Manifestations

Conditions
-----------------
Systemic Lupus Erythematosus

Intervention / Treatment
-----------------
* Diagnostic Test: anti dfs70 antibodies


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who fulfill the 2019 American College of Rheumatology/European League against Rheumatism classification criteria of Systemic Lupus Erythematous . (9) Patients who is able to give informed consent to join the study. • Exclusion Criteria: - - Any patient with any collagen disease other than systemic lupus erythematous

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| group A<br>systemic lupus erythematosus cases, diagnosed by SLICC criteria with negative levels of AntiDFS antibodies | Diagnostic Test: anti dfs70 antibodies<br>* blood sample is taken from SLE cases and is tested for antiDFS70 antibodies titre<br>|
| group B<br>systemic lupus erythematosus cases, diagnosed by SLICC criteria with positive levels of AntiDFS antibodies | Diagnostic Test: anti dfs70 antibodies<br>* blood sample is taken from SLE cases and is tested for antiDFS70 antibodies titre<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| antiDFS70 antibodies titre | serve as a non-histological biomarker for lupus nephritis subclass and activity status. | 1 year |